Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Ardelyx, Inc. manufactures biotechnological drugs. The Company offers pharmaceuticals to correct mineral metabolism imbalance and metabolic disorders by modulating the function of specific transporters, channels, and receptors located on the epithelia of the gastrointestinal tract. Ardelyx serves patients in the United States.
Website: ardelyx.com



Growth: Good revenue growth rate 27.6%, there is slowdown compared to average historical growth rates 146.0%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is negative, -7.3%. On average the margin is improving steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -4.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 15.2% higher than minimum and 61.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 6.9x by EV / Sales multiple , the company can be >100% undervalued

Insiders: For the last 3 months insiders sold company shares on $1.4 mln (-0.179% of cap.)

Key Financials (Download financials)

Ticker: ARDX
Share price, USD:  (0.0%)3.78
year average price 6.21  


year start price 6.59 2025-09-08

max close price 7.99 2026-01-21

min close price 3.71 2026-09-03

current price 3.78 2026-09-08
Common stocks: 163 088 367

Dividend Yield:  0.0%
EV / Sales: 1.6x
Margin (EBITDA LTM / Revenue): -7.3%
Fundamental value created in LTM:
Market Cap ($m): 616
Net Debt ($m): -60
EV (Enterprise Value): 556
Price to Book: 4.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-21seekingalpha.com

Ardelyx: Assessment Of Acquisition Rumors

2026-01-21zacks.com

Strength Seen in Ardelyx (ARDX): Can Its 15.0% Jump Turn into More Strength?

2026-01-12zacks.com

Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

2025-11-05seekingalpha.com

Ardelyx: Impressive Q3 Record Growth - Why I Buy

2025-11-04seekingalpha.com

Ardelyx: A Long Overdue Rally

2025-10-30seekingalpha.com

Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript

2025-10-30zacks.com

Ardelyx (ARDX) Reports Break-Even Earnings for Q3

2025-10-13globenewswire.com

Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

2025-09-08seekingalpha.com

Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

2025-09-03seekingalpha.com

Ardelyx, Inc. (ARDX) Presents At Citi's Biopharma Back To School Conference Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-08-04 2024-10-31 2024-08-01 2024-05-02 2023-10-31 2023-08-02 2023-05-03 2022-11-03
acceptedDate 2025-10-30 16:16:56 2025-08-04 16:41:51 2025-02-20 12:08:28 2024-10-31 16:06:05 2024-08-01 16:05:38 2024-05-02 16:05:25 2024-02-22 16:40:06 2023-10-31 07:03:07 2023-08-02 07:02:50 2023-05-03 16:07:02 2023-03-02 16:05:56 2022-11-03 16:08:35 2022-02-28 16:05:54 2021-03-08 08:14:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 110M 98M 334M 98M 73M 46M 124M 56M 22M 11M 52M 5M 10M 8M
costOfRevenue 1M 12M 51M 16M 10M 8M 18M 7M 3M 2M 4M 732 000 1 000 000 145 000
grossProfit 109M 85M 283M 83M 63M 38M 107M 49M 19M 10M 48M 4M 9M 7M
grossProfitRatio 0.988 0.873 0.84 0.863 0.836 0.875 0.844 0.865 0.853
researchAndDevelopmentExpenses 18M 16M 52M 15M 12M 10M 36M 9M 8M 9M 35M 7M 91M 65M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 77M 19M 72M 33M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 84M 84M 259M 65M 65M 53M 134M 33M 27M 27M 77M 19M 72M 33M
otherExpenses 3M 0 0 0 2M 2M 0 1M 2M 1M 0 0 0 0
operatingExpenses 104M 100M 311M 80M 77M 63M 170M 41M 35M 36M 112M 26M 163M 98M
costAndExpenses 106M 112M 362M 96M 87M 71M 188M 48M 39M 37M 116M 27M 164M 98M
interestIncome 0 0 0 0 0 0 0 2M 0 0 0 0 0 0
interestExpense 6M 7M 20M 5M 5M 4M 9M -1M 2M 2M 5M 2M 5M 5M
depreciationAndAmortization 905 000 631 000 2M 544 000 569 000 435 000 1M 291 000 642 000 1M 1M 1M 3M 4M
ebitda 6M -12M -17M 5M -11M -24M -55M 7M -14M -25M -61M -21M -151M -85M
ebitdaratio 0.053 -0.122 0.051 -0.178 -0.527 0.131 -0.646 -2.178 -4.121
operatingIncome 5M -14M -28M 2M -14M -25M -63M 7M -17M -26M -64M -22M -154M -91M
operatingIncomeRatio 0.042 -0.147 0.023 -0.186 -0.536 0.131 -0.744 -2.293 -4.388
totalOtherIncomeExpensesNet -6M -5M -11M -3M -3M -2M -2M -569 000 2M -695 000 -3M -1M -4M -4M
incomeBeforeTax -867 000 -19M -39M -766 000 -16M -26M -66M 7M -17M -27M -67M -23M -158M -94M
incomeBeforeTaxRatio -0.008 -0.195 -0.008 -0.224 -0.574 0.121 -0.767 -2.354 -4.591
incomeTaxExpense 102 000 1000 266 000 43 000 67 000 121 000 547 000 200 000 4M 14 000 8000 1M 4000 2000
netIncome -969 000 -19M -39M -809 000 -16M -27M -66M 7M -17M -27M -67M -24M -158M -94M
netIncomeRatio -0.009 -0.195 -0.008 -0.225 -0.576 0.118 -0.767 -2.355 -4.795
eps -0.004 -0.08 -0.17 -0.003 -0.07 -0.11 -0.3 0.03 -0.08 -0.13 -0.42 -0.14 -1.52 -1.05
epsdiluted -0.004 -0.08 -0.003 -0.07 -0.11 0.029 -0.08 -0.13 -0.14
weightedAverageShsOut 242M 240M 235M 236M 235M 233M 219M 223M 215M 207M 159M 165M 104M 90M
weightedAverageShsOutDil 242M 240M 235M 236M 235M 233M 219M 228M 215M 207M 159M 165M 104M 90M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-22 2023-03-02 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome -20M -9M -5M -5M -5M
ebit -19M -57M -62M -154M -89M
nonOperatingIncomeExcludingInterest -9M -7M -2M -687 000 -2M
netIncomeFromContinuingOperations -39M -66M -67M -158M -94M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -39M -66M -67M -158M -94M
epsDiluted -0.17 -0.3 -0.42 -1.52 -1.05

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-08-04 2024-10-31 2024-08-01 2024-05-02 2023-10-31 2023-08-02 2023-05-03 2022-11-03
acceptedDate 2025-10-30 16:16:56 2025-08-04 16:41:51 2025-02-20 12:08:28 2024-10-31 16:06:05 2024-08-01 16:05:38 2024-05-02 16:05:25 2024-02-22 16:40:06 2023-10-31 07:03:07 2023-08-02 07:02:50 2023-05-03 16:07:02 2023-03-02 16:05:56 2022-11-03 16:08:35 2022-02-28 16:05:54 2021-03-08 08:14:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 43M 90M 65M 47M 42M 36M 21M 34M 30M 92M 96M 62M 72M 91M
shortTermInvestments 200M 148M 185M 143M 144M 166M 163M 131M 98M 38M 28M 29M 44M 95M
cashAndShortTermInvestments 243M 238M 250M 190M 186M 203M 184M 165M 128M 130M 124M 91M 117M 186M
netReceivables 77M 63M 58M 53M 37M 28M 22M 43M 9M 12M 8M 5M 502 000 0
inventory 25M 22M 21M 11M 14M 10M 12M 9M 8M 5M 3M 1M 0 0
otherCurrentAssets 23M 28M 11M 29M 26M 17M 8M 7M 5M 6M 5M 23M 1 0
totalCurrentAssets 368M 352M 356M 284M 263M 258M 246M 241M 162M 167M 154M 120M 134M 195M
propertyPlantEquipmentNet 7M 7M 4M 5M 5M 6M 7M 8M 8M 9M 11M 11M 15M 4M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 2M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 111M 108M 75M 79M 75M 79M 45M 41M 41M 41M 26M 13M 1M 0
totalNonCurrentAssets 118M 115M 79M 84M 80M 84M 51M 48M 49M 50M 36M 25M 16M 6M
otherAssets 0 0 0 0 1 1 0 0 0 0 0 0 0 0
totalAssets 486M 467M 436M 368M 343M 342M 298M 289M 211M 217M 190M 145M 150M 202M
accountPayables 18M 22M 16M 16M 11M 17M 11M 8M 5M 11M 11M 3M 4M 6M
shortTermDebt 1M 1M 0 5M 7M 4M 0 4M 31M 31M 27M 30M 32M 6M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 7M 6M 11M 7M 11M 7M 7M 4M 6M 6M 4M 4M 0 4M
otherCurrentLiabilities 57M 53M 50M 42M 34M 29M 15M 27M 19M 16M 10M 15M 1M 5M
totalCurrentLiabilities 83M 82M 78M 70M 62M 57M 50M 44M 62M 63M 66M 52M 53M 28M
longTermDebt 206M 205M 151M 102M 101M 100M 50M 30M 4M 5M 0 7M 0 47M
deferredRevenueNonCurrent 14M 12M 7M 13M 33M 34M 9M 10M 9M 11M 9M 9M 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 -22M -34M 0 14M 13M 0 0 0 0 0
otherNonCurrentLiabilities 29M 28M 26M 24M 23M 35M 20M 170 000 172 000 12M 11M -12M 5M 0
totalNonCurrentLiabilities 249M 246M 185M 139M 134M 135M 80M 55M 26M 29M 26M 26M 14M 47M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 5M 5M 3M 4M 5M 778 000 6M 7M 8M 9M 10M 11M 13M 3M
totalLiabilities 332M 327M 262M 210M 196M 191M 131M 98M 88M 92M 92M 78M 67M 75M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 24 000 24 000 24 000 24 000 23 000 23 000 23 000 23 000 22 000 21 000 20 000 19 000 13 000 9000
retainedEarnings -947M -946M -885M -890M -889M -873M -846M -817M -824M -807M -780M -791M -713M -555M
accumulatedOtherComprehensiveIncomeLoss 124 000 -38 000 57 000 185 000 -101 000 -20 000 224 000 -201 000 -210 000 -20 000 -54 000 -114 000 -6000 -4000
othertotalStockholdersEquity 1 101M 1 085M 1 048M 1 036M 1 024M 1 009M 947M 932M 858M
totalStockholdersEquity 154M 140M 173M 158M 147M 151M 167M 191M 123M 125M 98M 67M 83M 126M
totalEquity 154M 140M 173M 158M 147M 151M 167M 191M 123M 125M 98M 67M 83M 126M
totalLiabilitiesAndStockholdersEquity 486M 467M 368M 343M 342M 289M 211M 217M 145M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 486M 467M 436M 368M 343M 342M 298M 289M 211M 217M 190M 145M 150M 202M
totalInvestments 200M 148M 185M 143M 144M 166M 163M 131M 98M 38M 28M 29M 44M 98M
totalDebt 208M 207M 153M 104M 105M 105M 56M 34M 35M 36M 36M 37M 46M 55M
netDebt 165M 117M 89M 57M 63M 69M 35M 670 000 5M -57M -60M -24M -27M -36M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-22 2023-03-02 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 58M 22M 8M 502 000 0
otherReceivables 0 0 0 0 0
prepaids 16M 19M 14M 16M 8M
totalPayables 16M 11M 11M 4M 6M
otherPayables 0 0 0 0 0
accruedExpenses 0 13M 10M 12M 5M
capitalLeaseObligationsCurrent 2M 4M 4M 3M 2M
capitalLeaseObligationsNonCurrent 1M 2M 6M 10M 413 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 059M 1 013M 879M 796M 681M
otherTotalStockholdersEquity 0 0 0 -0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX ARDX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-30 2025-08-04 2024-10-31 2024-08-01 2024-05-02 2023-10-31 2023-08-02 2023-05-03 2022-11-03
acceptedDate 2025-10-30 16:16:56 2025-08-04 16:41:51 2025-02-20 12:08:28 2024-10-31 16:06:05 2024-08-01 16:05:38 2024-05-02 16:05:25 2024-02-22 16:40:06 2023-10-31 07:03:07 2023-08-02 07:02:50 2023-05-03 16:07:02 2023-03-02 16:05:56 2022-11-03 16:08:35 2022-02-28 16:05:54 2021-03-08 08:14:57
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -969 000 -19M -39M -809 000 -16M -27M -66M 7M -17M -27M -67M -23M -158M -94M
depreciationAndAmortization 905 000 631 000 2M 544 000 569 000 435 000 1M 291 000 642 000 -3000 1M 628 000 1M 2M
deferredIncomeTax 0 0 0 0 0 0 0 0 -499 000 0 0 0 -190 000 315 000
stockBasedCompensation 13M 12M 37M 9M 11M 8M 14M 3M 3M 3M 11M 2M 12M 11M
changeInWorkingCapital -9M -19M -49M 33M -15M -19M -43M -33M -2M -23M -20M -6M -12M -3M
accountsReceivables -14M -16M -36M -16M -9M -6M -14M -34M 3M -4M -7M 415 000 -502 000 750 000
inventory -6M -17M -42M -2M -5M -29M -21M 414 000 -3M -17M -28M -5M -10M -750 000
accountsPayables -3M 8M 5M 4M -6M 6M 279 000 2M -5M -346 000 7M -1M -1M 3M
otherWorkingCapital 14M 7M 23M 47M 5M 11M -8M -1M 3M -2M 9M -57 000 300 000 -7M
otherNonCashItems -3M 348 000 4M -42M 32M 39M 5M 910 000 1M 2M 5M 1M 4M 3M
netCashProvidedByOperatingActivities 365 000 -25M -45M 501 000 -19M -36M -90M -21M -15M -45M -70M -25M -153M -81M
investmentsInPropertyPlantAndEquipment -156 000 -650 000 -1M -137 000 -131 000 -150 000 -344 000 -194 000 -93 000 -14 000 -55 000 0 -2M -324 000
acquisitionsNet 0 0 0 0 0 0 0 33M 0 0 0 0 -53M 31M
purchasesOfInvestments -114M -23M -195M -40M -23M -34M -215M -50M -67M -21M -50M -18M -73M -151M
salesMaturitiesOfInvestments 63M 58M 178M 42M 47M 32M 84M 17M 8M 11M 67M 17M 126M 120M
otherInvestingActivites 0 0 0 24M -2M -33M 0 0 530 000
netCashUsedForInvestingActivites -51M 35M 2M 24M -3M -33M -59M -10M -832 000
debtRepayment 0 49M 0 0 -50M 0 0 0 0
commonStockIssued 0 988 000 3M 2M 3M 57M 11M 51M 34M
commonStockRepurchased 0 0 0 0 0 3M 0 670 000 0 200 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 3M 0 0 2M 50M -58M 149 000 0 112 000
netCashUsedProvidedByFinancingActivities 3M 50M 3M 2M 53M 58M 12M 51M 34M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 64M 149M 0 0 0 0 0
netChangeInCash -47M 59M 43M 6M 6M 15M -75M 4M -62M -4M 24M 8M -19M -90M
cashAtEndOfPeriod 43M 90M 65M 47M 42M 36M 21M 34M 30M 92M 96M 62M 72M 91M
cashAtBeginningOfPeriod 90M 31M 21M 42M 36M 21M 96M 30M 92M 96M 72M 53M 91M 181M
operatingCashFlow 365 000 -25M -45M 501 000 -19M -36M -90M -21M -15M -45M -70M -25M -153M -81M
capitalExpenditure -156 000 -650 000 -1M -137 000 -131 000 -150 000 -344 000 -194 000 -93 000 -14 000 -55 000 0 -2M -324 000
freeCashFlow 209 000 -26M -46M 364 000 -20M -36M -90M -22M -15M -45M -70M -25M -154M -82M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-20 2024-02-22 2023-03-02 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 2M 53M -31M
netCashProvidedByInvestingActivities -18M -131M 18M 51M -31M
netDebtIssuance 99M 22M -6M -19M -125 000
longTermNetDebtIssuance 99M 22M -6M -19M -125 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 8M 119M 72M 101M 21M
netCommonStockIssuance 8M 119M 72M 101M 21M
commonStockIssuance 8M 119M 72M 101M 21M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -1 000 000 5M 10M 1M 2M
netCashProvidedByFinancingActivities 107M 146M 75M 83M 23M
incomeTaxesPaid 266 000 51 000 6000 4000 1000
interestPaid 11M 4M 3M 3M 4M

Earning call transcript

2025 q3
2025-10-30 ET (fiscal 2025 q3)
2025 q2
2025-08-04 ET (fiscal 2025 q2)
2025 q1
2025-05-01 ET (fiscal 2025 q1)
2024 q4
2025-02-20 ET (fiscal 2024 q4)
2024 q3
2024-10-31 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-02 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-10-31 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-03-02 ET (fiscal 2022 q4)
2022 q3
2022-11-06 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-08-06 ET
Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-23 ET
Ardelyx to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-05-19 12:01 ET
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
2026-05-07 12:01 ET
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
2026-04-30 ET
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-27 ET
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
2026-04-23 ET
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
2026-04-20 ET
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
2026-04-16 ET
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
2026-04-01 ET
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
2026-03-12 ET
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
2026-03-09 ET
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
2026-03-04 ET
Ardelyx to Participate in Upcoming Investor Conferences
2026-02-24 ET
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
2026-02-19 ET
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-05 13:00 ET
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
2026-02-03 13:29 ET
Ardelyx Receives New Patent for Tenapanor
2026-01-28 ET
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
2026-01-08 ET
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
2025-11-07 ET
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week
2025-11-05 ET
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London
2025-11-04 ET
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
2025-10-30 ET
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
2025-10-28 ET
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
2025-10-21 ET
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
2025-10-13 ET
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
2025-10-13 ET
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
2025-08-25 ET
Ardelyx to Participate in Upcoming Investor Conferences
2025-08-04 ET
Ardelyx Announces Changes to the Executive Leadership Team
2025-08-04 ET
Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-21 ET
Ardelyx to Report Second Quarter 2025 Financial Results on August 4, 2025
2025-06-02 ET
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer
2025-05-21 ET
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025
2025-05-06 ET
Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference
2025-05-01 ET
Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update
2025-04-29 ET
Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors
2025-04-24 ET
Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference
2025-04-17 ET
Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025
2025-04-10 ET
Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings
2025-03-31 ET
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings
2025-03-13 ET
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award
2025-02-26 ET
Tenapanor Approved in China for Hyperphosphatemia
2025-02-25 ET
Ardelyx to Participate in Upcoming Investor Conferences
2025-02-20 ET
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-19 ET
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
2025-01-30 ET
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
2025-01-13 ET
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities
2025-01-06 ET
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-11-20 ET
Ardelyx to Participate at the Piper Sandler 36th Annual Healthcare Conference
2024-11-08 ET
Ardelyx Responds to District Court Decision Granting Motion to Dismiss
2024-11-05 ET
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
2024-10-31 20:02 ET
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-10-28 20:05 ET
Ardelyx Presents Results from its IBS in America 2024 Supplemental Survey at the American College of Gastroenterology’s (ACG) Annual Meeting
2024-10-24 20:05 ET
Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week
2024-10-22 20:05 ET
Ardelyx Announces Launch of Gut Matters: Discoveries and Innovations, a New Podcast for the IBS-C Patient Community
2024-10-21 20:05 ET
Ardelyx Announces the Derek Forfang Patient Advocate Award to Recognize Advocates for the Chronic Kidney Disease Community
2024-10-17 12:00 ET
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
2024-10-15 12:00 ET
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the American Society of Nephrology’s Kidney Week
2024-10-09 12:05 ET
Ardelyx Announces Publication of a Review Article Exploring the Patient Burden and Therapeutic Landscape of IBS-C in the U.S. in Clinical and Experimental Gastroenterology
2024-09-05 12:00 ET
Ardelyx to Participate at the 2024 Cantor Global Healthcare Conference
2024-08-08 12:00 ET
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
2024-08-01 20:01 ET
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-07-31 12:02 ET
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
2024-07-18 12:00 ET
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
2024-07-17 21:10 ET
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
2024-07-02 19:12 ET
ARDX Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Ardelyx, Inc. for Potential Securities Law Violations
2024-07-02 11:00 ET
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
2024-06-28 12:17 ET
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
2024-05-30 20:02 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-05-22 12:02 ET
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
2024-05-21 12:02 ET
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
2024-05-16 12:01 ET
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
2024-05-14 20:02 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-05-07 12:01 ET
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
2024-05-02 20:02 ET
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-01 12:00 ET
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
2024-04-18 12:00 ET
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
2024-03-28 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-03-25 12:00 ET
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
2024-03-12 20:35 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-02-27 13:00 ET
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
2024-02-22 21:01 ET
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-02-01 13:00 ET
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
2024-01-12 12:56 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2024-01-08 13:00 ET
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
2024-01-03 13:03 ET
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
2023-12-20 13:00 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-11-21 21:02 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-11-21 13:01 ET
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
2023-11-15 21:02 ET
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
2023-11-13 21:02 ET
Ardelyx Announces Departure of Board Member
2023-11-10 13:05 ET
Ardelyx to Participate at the Jefferies London Healthcare Conference
2023-11-06 13:00 ET
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
2023-11-03 12:00 ET
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
2023-10-31 11:00 ET
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
2023-10-30 21:42 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-10-23 12:07 ET
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
2023-10-18 20:02 ET
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
2023-10-17 23:23 ET
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
2023-10-17 23:01 ET
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
2023-10-13 12:00 ET
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
2023-10-04 12:00 ET
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
2023-09-28 12:02 ET
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
2023-09-25 08:15 ET
Tenapanor for Hyperphosphatemia Approved in Japan
2023-09-11 12:00 ET
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
2023-09-08 12:00 ET
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-09-07 12:00 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-08-02 11:00 ET
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
2023-07-27 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-07-26 11:55 ET
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
2023-07-20 20:05 ET
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
2023-07-13 12:00 ET
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
2023-06-29 20:09 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-06-05 12:00 ET
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
2023-05-31 12:00 ET
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
2023-05-23 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-05-17 11:30 ET
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
2023-05-15 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-05-09 12:00 ET
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
2023-05-03 20:02 ET
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
2023-05-01 12:00 ET
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
2023-04-26 12:00 ET
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
2023-04-18 12:00 ET
Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)
2023-04-13 20:05 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2023-04-12 20:05 ET
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings
2023-03-02 21:02 ET
Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
2023-02-28 13:00 ET
Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
2023-02-27 13:15 ET
Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
2023-02-23 13:00 ET
Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
2023-02-02 21:20 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-12-29 12:00 ET
FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
2022-12-23 22:58 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-12-17 00:51 ET
Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
2022-11-22 13:00 ET
Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
2022-11-16 23:29 ET
Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
2022-11-16 14:00 ET
Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
2022-11-04 17:39 ET
National Kidney Foundation and Ardelyx, Inc. Survey Finds Dialysis Patients Struggle to Maintain Serum Phosphorus Levels
2022-11-03 20:01 ET
Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights
2022-11-03 14:00 ET
Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on ...
2022-11-02 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-10-31 12:00 ET
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan
2022-10-27 12:00 ET
Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022
2022-10-24 12:00 ET
Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting
2022-10-20 20:01 ET
Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022
2022-09-30 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-09-06 12:00 ET
Ardelyx to Participate in Upcoming Investor Conferences
2022-08-04 20:01 ET
Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights
2022-08-02 12:00 ET
Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference
2022-07-28 12:00 ET
Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022
2022-07-01 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-06-30 12:00 ET
Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners
2022-06-21 12:00 ET
Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022
2022-06-03 12:00 ET
Ardelyx to Present at the Jefferies 2022 Healthcare Conference
2022-05-24 20:01 ET
Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
2022-05-17 20:01 ET
Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022
2022-05-16 20:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-05-05 20:01 ET
Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights
2022-04-28 12:00 ET
Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022
2022-04-25 11:00 ET
Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)
2022-04-12 20:26 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-04-11 11:00 ET
Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor
2022-04-07 12:00 ET
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings
2022-04-04 12:00 ET
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults
2022-03-09 21:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2022-03-02 23:55 ET
Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference
2022-02-28 21:01 ET
Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
2022-02-24 13:00 ET
Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners
2022-02-22 13:00 ET
Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
2022-02-04 21:01 ET
Ardelyx, Inc. Reports Employment Inducement Grants
2021-11-30 12:00 ET
Ardelyx Launching IBSRELA® Second Quarter of 2022
2021-11-12 13:00 ET
Ardelyx Reports Third Quarter 2021 Financial Results
2021-11-11 21:05 ET
Ardelyx to Present at the Jefferies London Healthcare Conference
2021-11-05 12:00 ET
Ardelyx Reports Additional Positive Data Supporting Clinical Utility of Tenapanor at ASN's Kidney Week 2021
2021-11-04 12:00 ET
Ardelyx to Pursue Formal Dispute Resolution for Tenapanor
2021-10-29 12:00 ET
Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021
2021-10-13 12:00 ET
Ardelyx Provides Corporate Update Following Type A Meeting with FDA
2021-09-03 12:00 ET
Ardelyx Announces Publication of 52-Week Phase 3 PHREEDOM Trial
2021-08-13 12:00 ET
Ardelyx Reports Second Quarter 2021 Financial Results
2021-07-29 20:01 ET
Ardelyx Receives Complete Response Letter from U.S. FDA for New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2021-07-19 20:01 ET
Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2021-06-07 12:00 ET
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
2021-05-25 12:00 ET
Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference
2021-05-06 12:00 ET
Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights
2021-04-29 20:15 ET
Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2021-04-16 20:01 ET
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-04-14 12:00 ET
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
2021-04-12 12:00 ET
Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
2021-03-30 20:01 ET
Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
2021-03-15 12:00 ET
Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors
2021-03-08 13:00 ET
Ardelyx Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
2021-03-02 00:04 ET
Thérapeutique Knight annonce le lancement commercial canadien de IBSRELA(MC) — un nouveau traitement innovant du syndrome de côlon irritable avec constipation
2021-02-17 13:00 ET
Ardelyx to Present at the 10th Annual SVB Leerink Global Healthcare Conference
2020-11-23 13:00 ET
Ardelyx to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-10 13:00 ET
Ardelyx to Present at the Jefferies Virtual London Healthcare Conference
2020-11-06 13:00 ET
Ardelyx to Webcast Virtual Analyst Day
2020-11-05 13:00 ET
Ardelyx Reports Third Quarter 2020 Financial Results and Business Highlights
2020-10-22 14:00 ET
Ardelyx and Kyowa Kirin Highlight New Data Supporting the Clinical Safety and Efficacy of First-In-Class, Phosphate Absorption Inhibitor Tenapanor at ASN's Kidney Week 2020
2020-10-22 12:00 ET
Ardelyx Launches 'Can We Do Better?' Campaign at ASN's Kidney Week 2020
2020-10-12 12:00 ET
Ardelyx Announces Data Supporting Efficacy and Safety of Tenapanor, a First-in-Class Phosphate Absorption Inhibitor, to be Presented at ASN's Kidney Week 2020
2020-09-15 12:00 ET
Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2020-09-08 12:00 ET
Ardelyx to Participate in Three Upcoming Investor Conferences in September
2020-08-06 12:00 ET
Ardelyx Reports Second Quarter 2020 Financial Results and Recent Business Highlights
2020-08-03 12:00 ET
Ardelyx Selected as a Finalist in the Fierce Innovation Awards for the Development of its First-in-Class Product Candidate Tenapanor
2020-06-30 12:00 ET
Ardelyx Announces Submission of New Drug Application to the U.S. FDA for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
2020-06-15 12:00 ET
Ardelyx Announces Positive Second Data Analysis from Ongoing NORMALIZE Phase 4 Study Evaluating Tenapanor in CKD Patients on Dialysis
2020-06-10 00:45 ET
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-06-08 20:01 ET
Ardelyx Appoints Veteran Biopharma Executive, Justin Renz, as Chief Financial Officer
2020-05-26 13:00 ET
Ardelyx to Present at the Jefferies 2020 Virtual Healthcare Conference
2020-05-21 21:23 ET
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2020-05-18 20:01 ET
Ardelyx Strengthens Management Team with Appointment of Susan Rodriguez as Chief Commercial Officer
2020-05-07 20:02 ET
Ardelyx Reports First Quarter 2020 Financial Results and Recent Business Highlights
2020-03-16 13:00 ET
Ardelyx Appoints Onaiza Cadoret-Manier to its Board of Directors
2020-03-06 21:02 ET
Ardelyx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
2020-02-26 13:00 ET
Ardelyx to Present at the Cowen and Company 40th Annual Health Care Conference
2020-02-19 13:00 ET
Ardelyx to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2019-12-05 04:32 ET
Ardelyx Announces Pricing of Upsized Public Offering of Common Stock
2019-12-04 21:56 ET
Ardelyx Announces Proposed Public Offering of Common Stock
2019-12-03 12:25 ET
Ardelyx Announces Positive Topline Results from Pivotal Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis
2019-12-02 21:01 ET
Ardelyx to Host Conference Call on December 3 to Review Results from the Pivotal Phase 3 PHREEDOM Study
2019-11-26 21:00 ET
Ardelyx to Present at the Piper Jaffray 31st Annual Healthcare Conference
2019-11-25 23:00 ET
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
2019-11-06 21:05 ET
Ardelyx Announces Presentation at Kidney Week 2019
2019-11-06 21:02 ET
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
2019-10-10 20:00 ET
Ardelyx to Host Analyst Day in New York
2019-09-17 20:01 ET
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
2019-09-03 12:00 ET
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
2019-09-02 20:00 ET
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
2019-08-09 12:00 ET
Ardelyx Reports Second Quarter 2019 Financial Results and Recent Business Highlights
2019-05-30 13:00 ET
Ardelyx to Present at the Jefferies 2019 Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 10
2026-08-06 20:12 ET
Ardelyx published news for 2026 q2
SEC form 8
2026-08-06 20:09 ET
Ardelyx published news for 2026 q2
SEC form 8
2026-08-06 20:09 ET
Ardelyx published news for 2026 q2
SEC form 8
2026-08-06 20:09 ET
Ardelyx published news for 2026 q2
SEC form 10
2026-04-30 20:05 ET
Ardelyx published news for 2026 q1
SEC form 8
2026-04-30 20:02 ET
Ardelyx published news for 2026 q1
SEC form 8
2026-04-30 20:02 ET
Ardelyx published news for 2026 q1
SEC form 8
2026-04-30 20:02 ET
Ardelyx published news for 2026 q1
SEC form 10
2026-02-19 16:05 ET
Ardelyx published news for 2025 q4
SEC form 8
2026-02-19 16:03 ET
Ardelyx published news for 2025 q4
SEC form 8
2026-02-19 16:03 ET
Ardelyx reported for 2025 q4
SEC form 8
2026-02-19 16:03 ET
Ardelyx published news for 2025 q4
SEC form 8
2026-01-08 13:34 ET
Ardelyx published news for 2025 q4
SEC form 10
2025-10-30 20:16 ET
Ardelyx reported for 2025 q3
SEC form 8
2025-10-30 20:09 ET
Ardelyx reported for 2025 q3
SEC form 8
2025-10-30 20:09 ET
Ardelyx published news for 2025 q3
SEC form 10
2025-08-04 20:41 ET
Ardelyx reported for 2025 q2
SEC form 8
2025-08-04 20:22 ET
Ardelyx reported for 2025 q2
SEC form 8
2025-08-04 20:22 ET
Ardelyx published news for 2025 q2
SEC form 8
2025-08-04 20:22 ET
Ardelyx published news for 2025 q2
SEC form 8
2025-07-03 12:49 ET
Ardelyx published news for 2025 q2
SEC form 8
2025-07-03 12:49 ET
Ardelyx published news for 2025 q2
SEC form 10
2025-05-01 20:04 ET
Ardelyx published news for 2025 q1
SEC form 8
2025-05-01 20:03 ET
Ardelyx published news for 2025 q1
SEC form 8
2025-05-01 20:03 ET
Ardelyx reported for 2025 q1
SEC form 10
2025-05-01 00:00 ET
Ardelyx published news for 2025 q1
SEC form 10
2025-02-20 12:08 ET
Ardelyx published news for 2024 q4
SEC form 8
2025-02-20 07:34 ET
Ardelyx reported for 2024 q4
SEC form 8
2025-02-20 07:34 ET
Ardelyx published news for 2024 q4
SEC form 10
2025-02-20 00:00 ET
Ardelyx published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Ardelyx published news for 2024 q4
SEC form 10
2024-10-31 16:06 ET
Ardelyx reported for 2024 q3
SEC form 8
2024-10-31 16:04 ET
Ardelyx reported for 2024 q3
SEC form 8
2024-10-31 16:04 ET
Ardelyx published news for 2024 q3
SEC form 10
2024-08-01 16:05 ET
Ardelyx reported for 2024 q2
SEC form 8
2024-08-01 16:03 ET
Ardelyx reported for 2024 q2
SEC form 8
2024-08-01 16:03 ET
Ardelyx published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
Ardelyx reported for 2024 q2
SEC form 10
2024-05-02 16:05 ET
Ardelyx published news for 2024 q1
SEC form 8
2024-05-02 16:04 ET
Ardelyx published news for 2024 q1
SEC form 8
2024-05-02 16:04 ET
Ardelyx reported for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Ardelyx published news for 2024 q1
SEC form 10
2024-02-22 16:40 ET
Ardelyx published news for 2023 q4
SEC form 8
2024-02-22 16:04 ET
Ardelyx published news for 2023 q4
SEC form 8
2024-02-22 16:04 ET
Ardelyx reported for 2023 q4
SEC form 10
2024-02-22 00:00 ET
Ardelyx published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Ardelyx published news for 2023 q4
SEC form 10
2023-10-31 07:03 ET
Ardelyx reported for 2023 q3
SEC form 8
2023-10-31 07:02 ET
Ardelyx reported for 2023 q3
SEC form 10
2023-10-31 00:00 ET
Ardelyx reported for 2023 q3
SEC form 10
2023-08-02 07:02 ET
Ardelyx reported for 2023 q2
SEC form 6
2023-08-02 07:01 ET
Ardelyx reported for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Ardelyx reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Ardelyx reported for 2023 q2
SEC form 6
2023-06-20 16:05 ET
Ardelyx published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
Ardelyx reported for 2023 q1
SEC form 10
2023-05-03 00:00 ET
Ardelyx reported for 2023 q1
SEC form 6
2023-04-26 16:15 ET
Ardelyx published news for 2023 q1
SEC form 6
2023-04-14 16:17 ET
Ardelyx published news for 2023 q1
SEC form 10
2023-03-02 00:00 ET
Ardelyx reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
Ardelyx reported for 2022 q4
SEC form 10
2022-11-03 00:00 ET
Ardelyx reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
Ardelyx reported for 2022 q3
SEC form 8
2022-08-04 00:00 ET
Ardelyx reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Ardelyx reported for 2022 q2
SEC form 8
2022-05-05 00:00 ET
Ardelyx reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Ardelyx reported for 2022 q1
SEC form 8
2022-02-28 00:00 ET
Ardelyx published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Ardelyx published news for 2021 q4
SEC form 8
2021-11-12 00:00 ET
Ardelyx published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Ardelyx published news for 2021 q3
SEC form 10
2021-08-13 00:00 ET
Ardelyx published news for 2021 q2
SEC form 8
2021-08-13 00:00 ET
Ardelyx published news for 2021 q2
SEC form 8
2021-07-19 00:00 ET
Ardelyx published news for 2021 q2
SEC form 10
2021-05-06 00:00 ET
Ardelyx published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Ardelyx published news for 2021 q1